New cancer drug costs $90,000 monthly, raising concerns over healthcare greed

This report highlights the case of James Howard from Vancouver, who is paying $90,000 per month for a new pancreatic cancer drug that may only extend his life by a few months. The high cost of this treatment has sparked criticism from doctors who view the pricing as driven by greed rather than patient care. This situation reflects broader concerns about the affordability and ethics of cancer drug pricing in Canada.

Originally published by gnews